NASDAQ:ALKS
Alkermes plc Stock News
$27.25
+0.470 (+1.76%)
At Close: Mar 27, 2024
How Alkermes (ALKS) Stock Stands Out in a Strong Industry
09:47am, Wednesday, 23'rd Nov 2022
Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
02:13pm, Thursday, 03'rd Nov 2022 Benzinga
Upgrades
According to Baird, the prior rating for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) was changed from Neutral to Outperform. Ultragenyx Pharmaceutical earned $2.43 in the third quarter, comp
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
03:43pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Alkermes plc (ALKS) Q3 2022 Earnings Call Transcript
01:41pm, Wednesday, 02'nd Nov 2022
Alkermes plc (NASDAQ:ALKS ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Sandra Coombs - SVP, IR & Corporate Affairs Richard Pops - CEO Iain Brown - CFO Todd Nicho
Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss
12:48pm, Wednesday, 02'nd Nov 2022
Alkermes' (ALKS) earnings meet estimates in the third quarter of 2022 while revenues miss the same. The company tightens total revenue guidance for 2022.
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
02:00pm, Friday, 28'th Oct 2022 Zacks Investment Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes, Allakos See Activist Action
06:35pm, Friday, 14'th Oct 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
02:37pm, Friday, 14'th Oct 2022 Benzinga
Upgrades
For Enviva Inc (NYSE:EVA), Citigroup upgraded the previous rating of Neutral to Buy. For the second quarter, Enviva had an EPS of $0.26, compared to year-ago quarter EPS of $0.24. The curren
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
11:24am, Friday, 14'th Oct 2022 Benzinga
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.2
Alkermes: Nothing Stands Out As Interesting
03:02pm, Monday, 26'th Sep 2022
Alkermes plc has a slew of revenue earning products in CNS. It is refocusing itself on oncology assets.
Alkermes (ALKS) Gains As Market Dips: What You Should Know
09:50pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Alkermes (ALKS) closed the most recent trading day at $24.51, moving +0.62% from the previous trading session.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
02:20pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
12:46pm, Thursday, 18'th Aug 2022 Zacks Investment Research
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
12:40pm, Thursday, 18'th Aug 2022 Zacks Investment Research
AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
09:47am, Thursday, 18'th Aug 2022
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.